[{"arm_notes": "", "treatment_id": null, "treatment_name": "PHASE A: Treatment of 5 patients with Nomacopan subcutaneously for at least 7 days; until completing 14 days. When the fifth patient completes treatment or withdraws from the study; a drug safety monitoring board will meet and decide whether the study should be continued; terminated or modified. If it has been decided to proceed; phase B begins.PHASE B: 60 patients. 40 patients will receive Nomacopan subcutaneously for at least 7 days; until they are 14 days old. 20 patients will receive placebo subcutaneously at least 7 days; until they are 14 days old.Monitoring: Routine cardiorespiratory monitoring of the patient will be performed twice a day and with the appropriate adjustment to oxygen supplementation to ensure oxygen saturation greater than or equal to 93%.;Drug;E02.319", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 899, "treatment_name": "Nomacopan", "treatment_type": "Immunosuppressants", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]